Myriad Genetics Acquires Counsyl, a Women’s Health Lab

Myriad Genetics (NASDAQ: MYGN) agreed to pay $375 million to acquire privately held Counsyl, Inc., which operates a high-complexity clinical laboratory dedicated to women’s health. Counsyl’s lab services include carrier and non-invasive prenatal screening, including its Foresight Carrier Screen, Prelude Prenatal Screen, Reliant Cancer Screen, as well as supporting services through Counsyl Complete, a suite […]

Myriad Genetics Eyes GeneSight

Myriad Genetics Inc. (NASDAQ: MYGN), which specializes in molecular diagnostics and personalized medicine, started off August with the acquisition of privately-held Assurex Health Inc., an informatics-based, personalized medicine company that specializes in pharmacogenomics, a study of the genetic factors that influence an individual’s response to drug treatments, for behavioral health and chronic pain conditions. Assurex was […]